The Effect of Probiotic and Omega-3 Supplements on Total Oxidant and Total Antioxidant Levels in Experimental Colitis

Year 2021, Volume: 11 Issue: 2, 362 - 366, 30.06.2021

Havvanur YOLDAŞ İLKTAÇ Gül KIZILTAN Mehmet OZANSOY Ülkan KILIÇ Sine ÖZMEN TOĞAY İlknur KESKİN Ekrem Musa ÖZDEMİR Mehmet Yalçın GÜNAL

https://doi.org/10.33808/clinexphealthsci.865058

Cited By: 1

Abstract

Objective: Treatment of inflammatory bowel disease (IBD) usually involves medical therapy. For this reason, it is recommended to seek alternative treatment methods such as nutritional therapy. The aim of the study is to evaluate the effects of probiotics and omega-3 fatty acids on total oxidant and total antioxidant levels in an experimental colitis model.

Methods: Mice were randomly divided into five groups (n= 10/group) as healthy group, colitis group, group treated with probiotics (VSL#3), group treated with omega-3 (w-3), and group treated with both probiotics and omega-3. To induce experimental colitis, 200 mg/kg dinitrobenzene sulfonic acid (DNBS) + 30% ethanol combination was rectally administered to anesthetized mice. Total oxidant (TOS) and total antioxidant (TAS) levels were measured at the tissue level.

Results: Lower concentrations of TOS were observed in the probiotics groups (2.11±0.23 mmol H2O2 Eq/L), probiotics+omega-3 (2.56±1.18 mmol H2O2 Eq/L), and omega-3 (3.02±1.88 mmol H2O2 Eq/L) groups compared to the colitis group (3.11±0.91 mmol H2O2 Eq/L) (p>0.05). Higher TOS and TAS level were observed in the control colitis group compared to other groups; however, the differences were not statistically significant.

Conclusion: Our findings showed that TAS and TOS levels were positively affected by the use of probiotic supplements in IBD. It was determined that using w-3 alone was ineffective in decreasing TOS levels. Studies with higher dosages and longer treatment.

Keywords

probiotics, omega-3 fatty acids, total antioxidant level, total oxidant level, colitis, inflammatory bowel diseases

Supporting Institution

Scientific and Technological Research Council of Turkey (TUBITAK)

References

• 1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May;369(9573):1627–40.
• 2. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004 May;126(6):1518–32.
• 3. Sarma A, Rahaman Mallick A, Ghosh A. Free Radicals and Their Role in Different Clinical Conditions: An Overview. Int J Pharma Sci Res. 2010 Apr 1;1.
• 4. Satsangi J, Silverberg M, Vermeire S, Colombel J-F. Satsangi J, Silverberg MS, Vermeire S, Colombel JF.. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55: 749-753. Gut. 2006 Jul 1;55:749–53.
• 5. Buyukuslu N, Yigitbasi T. Reactive Oxygen Species and Oxidative Stress in Obesity. J Marmara Univ Inst Heal Sci. 2015;5(3):1.
• 6. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress. a randomized controlled trial. Am J Gastroenterol. 2003 Feb;98(2):348–53.
• 7. Catarzi S, Favilli F, Romagnoli C, Marcucci T, Picariello L, Tonelli F, et al. Oxidative state and IL-6 production in intestinal myofibroblasts of Crohn’s disease patients. Inflamm Bowel Dis. 2011 Aug;17(8):1674–84.
• 8. Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y, et al. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut [Internet]. 2003 May;52(5):720–8. Available from: https://pubmed.ncbi.nlm.nih.gov/12692059
• 9. Krzystek-Korpacka M, Neubauer K, Berdowska I, Zielinski B, Paradowski L, Gamian A. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. Inflamm Bowel Dis. 2010 Sep;16(9):1467–75.
• 10. Pinto MAS, Lopes MS-MS, Bastos STO, Reigada CLL, Dantas RF, Neto JCB, et al. Does active Crohn’s disease have decreased intestinal antioxidant capacity? J Crohns Colitis. 2013 Oct;7(9):e358-66.
• 11. Breganó JW, Dichi JB, Barbosa DS, El Kadri MZ, Matsuo T, Rodrigues MA, et al. Decreased total antioxidant capacity in plasma, but not tissue, in experimental colitis. Dig Dis Sci. 2009 Apr;54(4):751–7.
• 12. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MAC, van Hogezand RA, Lamers CBHW, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003 Sep;201(1):17–27.
• 13. Kruidenier L, Kuiper I, Lamers CBHW, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003 Sep;201(1):28–36.
• 14. Özgün E, Özgün GS, Eskiocak S, Yalçin Ö, Gökmen SS. Deneysel kolitte L-karnitinin serum paraoksonaz, arilesteraz ve laktonaz aktivitelerine ve oksidatif duruma etkisi. Turkish J Biochem. 2013;38(2):145–53.
• 15. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):316–28.
• 16. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005 Dec;38(12):1103–11.
• 17. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004 Apr;37(4):277–85.
• 18. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785–94.
• 19. Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007 Feb;4(2):78–91.
• 20. Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):101–8.
• 21. Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, Shaykhutdinov R, et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. PLoS One. 2012;7(2):e31238.
• 22. Ersan LY, Topçuoğlu E. Badem Sütü ile Zenginleştirilmiş Probiyotik Yoğurtların Mikrobiyolojik Microbiological and Some Physico-Chemical Properties of. Bursa Uludag Üniv Ziraat Fak Derg. 2019;33(2):321–39.
• 23. Martín R, Chain F, Miquel S, Lu J, Gratadoux J-J, Sokol H, et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis. 2014 Mar;20(3):417–30.
• 24. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS. 2007 Feb;115(2):81–103.
• 25. Girgin F, Karaoglu O, Erkuş M, Tüzün S, Ozütemiz O, Dinçer C, et al. Effects of trimetazidine on oxidant/antioxidant status in trinitrobenzenesulfonic acid-induced chronic colitis. J Toxicol Environ Health A. 2000 Apr;59(8):641–52.
• 26. Iborra M, Moret I, Rausell F, Bastida G, Aguas M, Cerrillo E, et al. Role of oxidative stress and antioxidant enzymes in Crohn’s disease. Biochem Soc Trans. 2011 Aug;39(4):1102–6.
• 27. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000 Jan;15(1):61–8.
• 28. Yıldız G. The Effects of Resveratrol Over Antioxiant Metabolism on TNBS-Induced Experimental Colitis [Internet]. Adnan Menderes University; 2013. Available from: http://adudspace.adu.edu.tr:8080/jspui/bitstream/11607/1295/1/GÜLSERAP YILDIZ.pdf
• 29. Özkan N. Sıçanlarda Trinitrobenzene Sulphonic Acid (TNBS) ile uyarılan kolit modelinde kefirin koruyucu etkinliğinin araştırılması. 2008.
• 30. Osman N, Adawi D, Molin G, Ahrne S, Berggren A, Jeppsson B. Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats. BMC Gastroenterol [Internet]. 2006 Oct 28;6:31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17069659
• 31. Mañé J, Lorén V, Pedrosa E, Ojanguren I, Xaus J, Cabré E, et al. Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm Bowel Dis. 2009 Aug;15(8):1155–63.
• 32. Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci. 2013 Mar;38(1):38–43.
• 33. Lamprecht M, Bogner S, Schippinger G, Steinbauer K, Fankhauser F, Hallstroem S, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012 Sep;9(1):45.
• 34. Mills SC, Windsor AC, Knight SC. The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes. Clin Exp Immunol [Internet]. 2005 Nov;142(2):216–28. Available from: https://pubmed.ncbi.nlm.nih.gov/16232207
• 35. Jacobson K, Mundra H, Innis SM. Intestinal responsiveness to experimental colitis in young rats is altered by maternal diet. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G13-20.
• 36. Morampudi V, Bhinder G, Wu X, Dai C, Sham HP, Vallance BA, et al. DNBS/TNBS colitis models: providing insights into inflammatory bowel disease and effects of dietary fat. J Vis Exp [Internet]. 2014 Feb 27;(84):e51297–e51297. Available from: https://pubmed.ncbi.nlm.nih.gov/24637969
• 37. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane database Syst Rev. 2007 Apr;(2):CD006320.
• 38. Nieto N, Torres MI, Fernández MI, Girón MD, Ríos A, Suárez MD, et al. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Dig Dis Sci. 2000 Sep;45(9):1820–7.
• 39. Maor I, Rainis T, Lanir A, Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn’s disease: distinction between active and non-active disease. Dig Dis Sci. 2008 Aug;53(8):2208–14.
• 40. D’Odorico A, Bortolan S, Cardin R, D’Inca’ R, Martines D, Ferronato A, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol. 2001 Dec;36(12):1289–94.
• 41. Peran L, Camuesco D, Comalada M, Bailon E, Henriksson A, Xaus J, et al. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J Appl Microbiol. 2007 Oct;103(4):836–44.
• 42. Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Diaz-Ropero MP, et al. Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol. 2005 Sep;11(33):5185–92.
• 43. Turner D, Shah PS, Steinhart AH, Zlotkin S, Griffiths AM. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis. 2011 Jan;17(1):336–45.
• 44. Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane database Syst Rev. 2014 Feb;(2):CD006320.
• 45. Barbosa DS, Cecchini R, El Kadri MZ, Rodríguez MAM, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition. 2003 Oct;19(10):837–42.